Document Detail

Clinical experiences with desmopressin for long-term treatment of nocturia.
MedLine Citation:
PMID:  15311028     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To our knowledge we report the first long-term use of desmopressin for nocturia. Patients previously responding to desmopressin in short-term studies were enrolled in this long-term open label study. MATERIALS AND METHODS: Patients received treatment for 10 or 12 months with the optimal desmopressin dose (0.1, 0.2 or 0.4 mg orally at bedtime). Patients were followed a further month without treatment. Of the patients completing the short-term study 132 males (92%) and 117 females (83%) were recruited, and 95 (72%) and 87 (75%), respectively, completed long-term treatment. RESULTS: The mean number of nocturnal voids was decreased in males and females throughout the study (1.3 to 1.6 and 1.2 to 1.3) compared with baseline (3.1 and 2.9, respectively). After followup the number of voids increased after treatment cessation. From baseline to 12 months the mean duration of the first sleep period gradually increased in males (157 to 288 minutes) and females (142 to 310 minutes). After followup the mean duration of the first sleep period decreased, confirming that it was a treatment related benefit. Desmopressin was well tolerated with few males (14%) or females (10%) withdrawing due to adverse events. Most adverse events were mild (44%) or moderate (44%) in severity. Four males experienced serious drug related adverse events, namely dizziness in 1, cardiac failure, headache and vomiting in 2, and chest pain and hypertension in 1. A female experienced 4 serious drug related adverse events, that is hyponatremia, headache, nausea and vertigo. Two patients had clinically significant hyponatremia. CONCLUSIONS: This long-term study shows that desmopressin is a generally well tolerated and effective treatment for nocturia.
G Lose; A Mattiasson; S Walter; O Lalos; P van Kerrebroeck; P Abrams; R Freeman
Related Documents :
7912948 - Effect of antagonizing residual neuromuscular block by neostigmine and atropine on post...
23227328 - Pathologic etiologies of late and very late stent thrombosis following first-generation...
11167438 - Randomised double-blind comparison of ondansetron and droperidol to prevent postoperati...
18824288 - Safety of ferumoxytol in patients with anemia and ckd.
25374678 - Venous thromboembolism following elective aesthetic plastic surgery: a longitudinal pro...
20333568 - Valve-sparing operation for aortic root aneurysm in patients with marfan syndrome.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study    
Journal Detail:
Title:  The Journal of urology     Volume:  172     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-16     Completed Date:  2004-09-03     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1021-5     Citation Subset:  AIM; IM    
Department of Gynaecology, Glostrup Hospital, Nordre Ringvej, DK-2600 Glostrup, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Deamino Arginine Vasopressin / adverse effects,  therapeutic use*
Middle Aged
Quality of Life
Urination / drug effects
Urination Disorders / drug therapy*,  physiopathology
Reg. No./Substance:
16679-58-6/Deamino Arginine Vasopressin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results.
Next Document:  Bicycle riding and its relationship to the development of erectile dysfunction.